In adults, angiogenesis is strictly restricted to processes associated with wound healing and the female reproductive cycle. When a balance between angiogenic and angiostatic factors is disrupted, however, uncontrolled angiogenic factors are released from tumor cells. These angiogenic factors, including vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), stimulate endothelial cell proliferation and invasion. Angiogenesis is observed in tumor growth and in angiogenesis-dependent diseases such as diabetic retinopathy and arthritis. Moreover, it has been known that tumor growth is dependent on blood supply, i.e., oxygen and nutrients. Consequently, an angiogenesis inhibitor may potentially be used as a new therapeutic agent for cancer treatment. 1) Several angiogenesis inhibitors such as TNP-470, marimastat, and SU5416, have been developed for targeting endothelial cell proliferation, invasion, and the VEGF receptor (VEGFR) signaling pathway, respectively. [2] [3] [4] Since hyaluronidase inhibitor has been anticipated to inhibit angiogenesis, 5) we have given attention to CHR (Fig. 1 ) which showed hyaluronidase inhibitory activity. 6) Hyaluronic acid, an abundant material in the extracellular matrix, is important for the maintenance of tissue constitution. It has been reported that hyaluronic acid fragments correlate to endothelial cell proliferation and migration, and finally lead to angiogenesis. 7-9) Moreover, mouse corneal angiogenesis is induced by hyaluronidase secreted from cancer cells. 6) Apigenin, a naturally occurring hyaluronidase inhibitor, has been reported to be an angiogenesis inhibitor. 6,10) Based on the above results, we thought that CHR may have antiangiogenic activity. In our continuing efforts to discover angiogenesis inhibitors for the development of new anticancer agents from natural resouces, 11, 12) we investigated the antiangiogenic activity of CHR. Herein we report our findings on the effects of CHR on in vitro and in vivo angiogenesis models.
used at passages 4-10. Human umbilical vein endothelial cells (HUVECs) were purchased from Clonetics Co. (Walkersville, San Diego, CA, U.S.A.) through Sankyo Junyaku Co., Ltd. (Tokyo, Japan) and cultured in endothelial cell basal medium (EBM-2) containing 10% fetal bovine serum (FBS). HUVECs were used at passages 4-10. Human fibrosarcoma HT1080 cells and human epidermoid carcinoma KB3-1 cells were cultured in DMEM supplemented with 10% FBS.
Cell Proliferation Assays BAECs were seeded at 1ϫ10 4 cells/well in 24-well plates then incubated in DMEM supplemented with 10% FBS. After 24 h, the medium was replaced with DMEM supplemented with 1% FBS in the presence of CHR, and 10 ng/ml human recombinant bFGF (BIOSOURCE Co., Camarillo, CA, U.S.A.) were added. After additional 72 h, the MTT assay was performed. HUVECs were seeded at 2.5ϫ10 4 cells/well in 24-well plates. After 24 h, the medium was replaced with EBM-2 supplemented with 0.5% FBS to quiesce the cells. After 24 h, CHR and 20 ng/ml human recombinant VEGF (R&D Systems, Minneapolis, MN, U.S.A.) were added. After 48 h, cells were harvested and counted on a Coulter counter. Cancer cells, HT1080 and KB3-1 (1ϫ10 4 cells/well), were seeded on 24-well plates and grown with or without CHR for an additional 48 h. Cell proliferation was performed as described in HUVEC experiments. CHR was dissolved in DMSO and diluted at the appropriate concentrations with the respective cultivation medium. The final concentration of DMSO was not more than 0.1% (v/v), which had no effect on the control group. The concentration inhibiting proliferation by 50% with respect to the control was estimated from graphic plots of a concentration dependent study and was defined as IC 50 expressed in micromole. The values were represented as the mean (nϭ6) of duplicates.
Chemotaxis Assay The chemotaxis assay of HUVECs was performed as described previously. 16) HUVECs (1ϫ10 6 cells/0.3 ml) were suspended in EBM-2 containing 0.5% FBS and seeded in the inner chamber of a Transwell insert (24-well chamber with 1.33 mg/ml fibronectin-coated 8 mm polycarbonate filter). The outer chamber was filled with VEGF (20 ng/ml) and CHR (1, 2.5, 10 mM). The chamber was incubated at 37°C for 4 h in 5% CO 2 in air. After incubation, migrated cells were stained with Giemsa reagent and counted with a microscope.
Immunoblotting Assay A mouse NIH 3T3 cell line overexpressing human KDR receptor was established previously. Confluent NIH 3T3/KDR cells were cultured in a sixwell plate supplemented with serum-depleted DMEM for 48 h. The cells were then preincubated with several concentrations of CHR for 3 h, followed by stimulation with 20 ng/ml VEGF for 10 min at 37°C. The cells were then rinsed with ice-cold PBS and lysed in HNTG buffer (50 mM HEPES, 150 mM NaCl, 1% Triton X-100 and 100% glycerol containing 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 mg/ml aprotin, 10 mg/ml leupeptin and 1 mM sodium vanadate). Cell lysates were subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-page) and transferred onto Immunobilon membranes (Millipore, Bedford, MA, U.S.A.). After transfer, blots were incubated with the blocking solution and probed with anti-phosphotyrosine (PY-20; ICN Biochemicals, Costa Mesa, CA, U.S.A.) antibody followed by washing. The protein contents were visualized using HRP-conjugated secondary antibodies, following by enhanced chemiluminescence (ECL; Amersham).
Mouse Corneal Neovascularization Assay The mouse corneal model was developed as previously described. 19) Briefly, mice (5-week-old BALB/cA) were purchased from CLEA Co. (Tokyo, Japan), and housed in an aseptic environment under controlled conditions of light and humidity, then received food and water ad libitum. Slow release pellets of Hydron N (Interferon Sciences, New Brunswick, NJ, U.S.A.) containing 200 ng mouse recombinant VEGF (R&D Systems, Minneapolis, MN, U.S.A.) were implanted into corneal pockets prepared by an incision placed 1 mm from the limbic vessel. On the day of implantation, animals were treated once daily with either an intraperitoneal or oral injection of CHR at 100 mg/kg/d. After 7 d, the animals were anesthetized, and the vessels were photographed.
RESULTS AND DISCUSSION
To determine whether CHR has an inhibitory effect on endothelial cell proliferation, we first examined the effect of CHR on the proliferation of BAECs. CHR inhibited the proliferation of BAECs in medium containing 10% FBS with an IC 50 of 7.6 mM. In addition, CHR showed an inhibitory effect on the proliferation of HUVECs with an IC 50 of 2.1 mM. However, CHR did not show significant inhibitory effects on the proliferation of KB3-1 (IC 50 value of 42.7 mM) cells. These results indicated that CHR more selectively inhibits the proliferation of endothelial cells than that of cancer cells. Since bFGF and VEGF are important angiogenic factors, we investigated whether CHR inhibits bFGF-or VEGF-mediated endothelial cell proliferation. As shown in Figs. 2A and  B , the bFGF-induced proliferation of BAECs, and VEGF-induced proliferation of HUVECs, were markedly inhibited by treatment with CHR (1 mM). However, more than 1.5-2.0 mM of CHR exhibited mild cytotoxic activities against the endothelial cells.
Because endothelial cell migration is an important process of angiogenesis, the ability of CHR to inhibit cell migration was assayed using a chemotaxis assay. As shown in Fig. 3 , CHR inhibited the VEGF-induced chemotaxis of HUVECs in a dose-dependent manner.
Because CHR exhibited potent antiangiogenic activities in vitro, we also tested the compound for its ability to inhibit angiogenesis in vivo. In a mouse corneal micropocket assay, VEGF-stimulated neovascularization was reduced in the mice treated with 100 mg/kg/d of CHR intraperitoneally (Fig.  5 ), but mice treated with this compound by oral injection did not exhibit a significant inhibitory effect at the same concentration (data not shown). At this dose, mice did not demonstrate weight loss or toxic effects.
Since it has been reported that cis-hinokiresinol is a racemic mixture and its bioactivity is also different, separation of the two enantiomers was performed using a chiral HPLC as described previously. 14) Two enantiomers, 3R-CHR and 3S-CHR, were obtained in an approximate ratio of 68 : 32. 3S-CHR exhibited selective inhibition three times higher than that of 3R-CHR against the proliferation of bFGF-induced BAECs.
In the present studies, we have demonstrated that CHR se-lectively inhibits both bFGF-and VEGF-induced angiogenic responses. First, we examined the effects of CHR on the proliferation of endothelial cells, and then identified that CHR selectively inhibits endothelial cell proliferation as compared with cancer cells. Moreover, CHR significantly inhibited both bFGF-and VEGF-induced endothelial cells proliferation. In addition, CHR significantly inhibited endothelial cell migration, an important step of the angiogenic process. VEGF, bFGF, and their receptors play a critical role in the angiogenesis process. Recently, angiogenesis inhibitors such as SU5416 and SU6668 have been developed for targeting the angiogenesis signaling pathway. SU5416 is a selective and potent inhibitor of KDR/Flk-1 receptor tyrosine kinase Fig. 2A .
Effects of CHR on bFGF-Induced Proliferation of BAECs
BAECs were seeded at 1.0ϫ10 4 cells/well in 24-well plates. After 24 h incubation, the medium was replaced with DMEM supplemented with 1% FBS in the presence of several dilutions of CHR and 1% FBS or bFGF (10 ng/ml). After 72 h, the MTT assay was performed. The experiment was performed in duplicate. Each column represents the meanϮS.D.
Fig. 2B. Effects of CHR on VEGF-Induced Proliferation of HUVECs
HUVECs were seeded at 2.5ϫ10 4 cells/well in 24-well plates. After 24 h incubation, the medium was replaced with EBM-2 supplemented with 0.5% FBS to quiesce the cells. After 24 h, several dilutions of CHR and 2.5% serum or VEGF (20 ng/ml) were added. After 48 h, cells were harvested and counted on a Coulter counter. The experiment was performed in triplicate. Each column represents the meanϮS.D.
Fig. 3. Effect of CHR on VEGF-Induced Chemotaxis of HUVECs
HUVECs were treated with VEGF (20 ng/ml) and CHR. The chamber was incubated at 37°C for 4 h in 5% CO 2 in air. After incubation, migrated cells were stained with Giemsa reagent and counted under a microscope. Each column represents the mean of six wells; bars indicate S.D. activity. SU5416 inhibits VEGF-driven mitogenesis and the migration of HUVECs without significant inhibition of the growth of a variety of tumor cells in vitro. However, nontoxic doses of SU5416 inhibited the tumor growth of multiple types of tumor xenografts in mice. 4) Moreover, SU6668, a receptor tyrosine kinase (RTK) inhibitor related to VEGFR KDR/Flk-1, FGF receptor (FGFR), and platelet-derived growth factor (PDGF) receptor (PDGFR), inhibited VEGFand FGF-dependent proliferation of HUVECs, and reduced the tumor growth of various human tumor xenografts. 13) Taken together, we examined the effects of CHR on the autophosphorylation of VEGFR, KDR and Flt-1 in a similar manner as costunolide, which is a sesquiterpene lactone from Saussurea lappa, which inhibits the VEGFR KDR/Flk-1 signaling pathway. 11) However, CHR only exhibited weak inhibitory activity against the VEGF-induced autophosphorylation of KDR/Flk-1 in NIH 3T3 cells overexpressing KDR/Flk-1, as shown in Fig. 4 . Having witnessed the significant antiangiogenic activity of CHR in vitro, we also confirmed that nontoxic dose of CHR inhibits VEGF-induced mouse corneal neovascularization. Current efforts are directed toward the development of CHR analogs and the elucidation of inhibitory effects on a human xenograft model.
It has recently been reported that CHR possesse appreciable estrogen receptor binding activity, and 3S-CHR exerts estrogenic activity seven times higher than that of 3R-CHR, as evaluated by a receptor binding assay. 14) The antiangiogenic activity of CHR may be concerned with the estrogen-like activity of 3S-CHR.
In conclusion, we propose that CHR may be useful for the treatment of human cancer and other angiogenesis-dependent diseases.
